Background: The optimal sequencing of CDK4/6 inhibitors combined with endocrine therapy for advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer remains uncertain, particularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback